LB Pharmaceuticals director granted 10,000 stock options

LB Pharmaceuticals director Rekha Hemrajani received a new stock option grant tied to the company’s common stock.

Rhea-AI Filing Summary

LB Pharmaceuticals director Rekha Hemrajani received a new stock option grant tied to the company’s common stock. The award covers 10,000 shares with an exercise price of $27.95 per share and expires on June 2, 2036.

These options were granted as compensation and not purchased on the open market. All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, if she remains in continuous service through that date. Following this grant, she holds 10,000 stock options directly.

Insights

Equity compensation analyst

Routine director option grant, no open‑market buying or selling.

The filing shows director Rekha Hemrajani receiving 10,000 stock options with a $27.95 exercise price, expiring on June 2, 2036. This is a compensation-related award, not a market transaction, and therefore carries limited signaling value for near-term stock sentiment.

The options vest 100% on the earlier of June 3, 2027 or the next annual stockholder meeting, contingent on continued service. Because there are no sales or open-market purchases and only a single grant, the economic impact is routine and best viewed as standard director equity compensation.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Hemrajani Rekha

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Stock options granted: 10,000 options Exercise price: $27.95 per share Underlying shares: 10,000 shares +3 more

6 metrics

Stock options granted 10,000 options Grant to director Rekha Hemrajani

Exercise price $27.95 per share Stock option strike price

Underlying shares 10,000 shares Common stock tied to options

Expiration date June 2, 2036 Option term end

Post-transaction derivative holdings 10,000 options Total options held after grant

Vest by date June 3, 2027 or next annual meeting 100% vesting trigger, continuous service required

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "27.9500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"100% of the shares underlying the option vest on the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rekha Hemrajani receive in this LB PHARMACEUTICALS (LBRX) Form 4 filing?

Rekha Hemrajani received a grant of stock options for 10,000 shares of LB PHARMACEUTICALS common stock. The award is a compensation-related grant, not an open-market purchase, and gives her the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new LBRX stock options granted to Rekha Hemrajani?

The new stock options have an exercise price of $27.95 per share. This means Hemrajani can buy up to 10,000 LB PHARMACEUTICALS shares at $27.95, regardless of future market price, once the options have vested and before they expire.

When do Rekha Hemrajani’s LBRX stock options vest according to the Form 4?

All 10,000 options vest on the earlier of June 3, 2027 or the date of LB PHARMACEUTICALS’ next annual meeting of stockholders. Vesting is conditional on Hemrajani’s continuous service with the company through that vesting date, aligning incentives with ongoing board involvement.

When do the newly granted LBRX stock options to Rekha Hemrajani expire?

The stock options granted to Hemrajani expire on June 2, 2036. She must wait for the options to vest, then exercise them before this expiration date; otherwise, the right to purchase the 10,000 underlying shares at $27.95 per share will lapse.

Does this LBRX Form 4 show any open-market buying or selling by Rekha Hemrajani?

No, the Form 4 only reports a grant of 10,000 stock options as compensation. There are no open-market purchases or sales of LB PHARMACEUTICALS common stock in this filing, so it primarily reflects a standard equity incentive award rather than trading activity.

How many LBRX derivative securities does Rekha Hemrajani hold after this stock option grant?

After the transaction, Hemrajani holds 10,000 stock options linked to LB PHARMACEUTICALS common stock. These options represent the right to acquire 10,000 shares at $27.95 per share once vested, giving her potential future equity exposure if she chooses to exercise them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hemrajani Rekha

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NEW YORK 10119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.95	06/03/2026		A		10,000		(1)	06/02/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Marc Panoff, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)